This is an open-label, single-arm, Phase 2 study which will evaluate the efficacy and safety
of niraparib and dostarlimab (TSR-042) combination in patients with metastatic, recurrent, or
unresectable solid tumor with a pathogenic, or presumed pathogenic, somatic homologous
recombination deficiency (HRD) gene mutation